INFO:
metastatic castration-sensitive prostate cancer (mCSPC), apalutamide treatment effect in TITAN patients with mCSPC, phase III randomised TITAN study, robust benefit with apalutamide plus ADT, Axel Merseburger.
Apalutamide plus Androgen Deprivation Therapy in Clinical Subgroups of Patients with Metastatic Castration-Sensitive Prostate Cancer: A Subgroup Analysis of the Randomised Clinical TITAN Study - Beyond the Abstract